Will the 2026 Nobel Prize in Medicine recognize GLP-1 or obesity-drug research on October 5?

Question

This market resolves YES if the official motivation or scientific background for the 2026 Nobel Prize in Physiology or Medicine explicitly recognises a discovery central to GLP-1 biology, incretin signalling or the development of GLP-1-receptor-based medicines used to treat diabetes or obesity. The laureate need not have invented a marketed drug, and the words “obesity drug” are not required, but the Nobel materials must directly connect the awarded work to GLP-1, incretins or therapies based on

Problyx · Accepted Answer

No — the community forecast puts this at 76%.

Problyx · Answer

Yes — the community forecast puts this at 24%.